Evidence map›Paper›PMID 28110021›Full record

ArticleMolecular and cellular neurosciences2017

The application of CRISPR technology to high content screening in primary neurons.

Ben L Callif, Brian Maunze, Nick L Krueger, Matthew T Simpson, Murray G Blackmore

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular neurosciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Reduced Expression of TMEM16A Impairs Nitric Oxide-Dependent ClFrontiers in cellular neuroscience · 2022
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Genome engineering for CNS injury and disease.Current opinion in biotechnology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ben L CallifDepartment of Biomedical Sciences, Marquette University, 53201, USA.
Brian MaunzeDepartment of Biomedical Sciences, Marquette University, 53201, USA.
Nick L KruegerDepartment of Biomedical Sciences, Marquette University, 53201, USA.
Matthew T SimpsonDepartment of Biomedical Sciences, Marquette University, 53201, USA.
Murray G BlackmoreDepartment of Biomedical Sciences, Marquette University, 53201, USA. Electronic address: murray.blackmore@marquette.edu.
Marquette University · US

Funding

Novel Gene Targets at the Intersection of Axon Regeneration and Cancer BiologyR21NS093278 · NINDS · MARQUETTE UNIVERSITY · PI BLACKMORE, MURRAY G · 2016 to 2017
$415k
NINDS NIH HHS R21 NS093278
6 · The paper itself

Abstract

Axon growth is coordinated by multiple interacting proteins that remain incompletely characterized. High content screening (HCS), in which manipulation of candidate genes is combined with rapid image analysis of phenotypic effects, has emerged as a powerful technique to identify key regulators of axon outgrowth. Here we explore the utility of a genome editing approach referred to as CRISPR (Clustered Regularly Interspersed Palindromic Repeats) for knockout screening in primary neurons. In the CRISPR approach a DNA-cleaving Cas enzyme is guided to genomic target sequences by user-created guide RNA (sgRNA), where it initiates a double-stranded break that ultimately results in frameshift mutation and loss of protein production. Using electroporation of plasmid DNA that co-expresses Cas9 enzyme and sgRNA, we first verified the ability of CRISPR targeting to achieve protein-level knockdown in cultured postnatal cortical neurons. Targeted proteins included NeuN (RbFox3) and PTEN, a well-studied regulator of axon growth. Effective knockdown lagged at least four days behind transfection, but targeted proteins were eventually undetectable by immunohistochemistry in >80% of transfected cells. Consistent with this, anti-PTEN sgRNA produced no changes in neurite outgrowth when assessed three days post-transfection. When week-long cultures were replated, however, PTEN knockdown consistently increased neurite lengths. These CRISPR-mediated PTEN effects were achieved using multi-well transfection and automated phenotypic analysis, indicating the suitability of PTEN as a positive control for future CRISPR-based screening efforts. Combined, these data establish an example of CRISPR-mediated protein knockdown in primary cortical neurons and its compatibility with HCS workflows.

Indexed as

AnimalsAnimals, NewbornCells, CulturedCerebral CortexClustered Regularly Interspaced Short Palindromic RepeatsGreen Fluorescent ProteinsNerve Tissue ProteinsNeuronal OutgrowthNeuronsPTEN PhosphohydrolaseRatsRats, Sprague-DawleyRNA, Small InterferingTransfectionTubulinenhanced green fluorescent proteinGreen Fluorescent ProteinsNerve Tissue ProteinsPTEN PhosphohydrolaseRNA, Small InterferingTubulinCortical neuronCRISPRHigh content screeningPTEN

Identifiers

PMID28110021
PMCPMC5393931
OpenAlexW2577984623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.